华蟾素胶囊联合唑来膦酸治疗恶性肿瘤骨转移疼痛的探讨  

Study on Cinobufacini capsules combined with zoledronic acid for treating bone metastases pain in malignant tumor

作　　者：李宏敏[1] 陈琳[1] 安宁[1] 于瑞莲[1] 何阳科[1] 郭万君 

机构地区：[1]四川省人民医院肿瘤科,成都610072 [2]四川省成都市青白江区人民医院,610300

出　　处：《检验医学与临床》2015年第16期2331-2332,2335,共3页Laboratory Medicine and Clinic

基　　金：四川省科技局课题(2014JY0043)

摘　　要：目的探讨华蟾素胶囊联合唑来膦酸治疗恶性肿瘤骨转移疼痛的效果。方法选取2012年6月至2014年6月四川省人民医院肿瘤科收治的恶性肿瘤骨转移疼痛患者60例作为研究对象,随机分为对照组和治疗组。对照组单纯使用唑来膦酸治疗,治疗组在对照组基础上联合使用华蟾素胶囊,比较2组患者的治愈率及不良反应发生率。结果治疗组的恶性肿瘤骨转移疼痛治愈率为66.7%(20/30),对照组为36.7%(11/30),2组比较差异有统计学意义(P<0.05);治疗组不良反应发生率为43.3%(13/30),与对照组的46.7%(14/30)比较,差异无统计学意义(P>0.05)。结论华蟾素胶囊联合唑来膦酸治疗恶性肿瘤骨转移疼痛的效果较为明显,具有一定的推广价值。Objective To investigate the effect of Cinobufacini capsules combined with zoledronic acid in trea- ting bone metastases pain in malignant tumor. Methods 60 patients with bone metastases pain of malignant tumor were selected in our hospital from June 2012 to June 2014 were selected as the research subjects and randomly divided into the control group and the treatment group, 30 cases in each group. The control group was treated with zoledronic acid,while on this basis the treatment group was combined with Cinobufotalin Capsules. The cure rate and the inci- dence of side and toxic effects were compared between the two groups. Results The total effective rates in the treat- ment group and the control group were 66.7 % （20/30） and 36.7 %（11/30）, the difference was statistically significant （P〈0.05）. The incidence rate of side and toxic effects in the treatment group and the control group were 43.3% （13/30） and 46.7% （14/30）, the difference was not statistically significant（P〉0.05）. Conclusion The effect of Cinobufacini capsules combined with zoledronic acid in treating bone metastases pain of malignant tumor is more sig- nificant and has certain popularization value.

关 键 词：华蟾素胶囊 唑来膦酸 骨转移 疼痛 

分 类 号：R738.1[医药卫生—肿瘤]